First-line tislelizumab for advanced or metastatic esophageal squamous cell carcinoma:A cost-effectiveness analysis

CONCLUSION: Tislelizumab plus chemotherapy as first-line treatment for advanced or metastatic ESCC is may be a cost-effective option compared to chemotherapy alone.PMID:38031985 | DOI:10.1080/14737167.2023.2290609

Source: Expert Review of Pharmacoeconomics and Outcomes Research - November 30, 2023 Category: Health Management Authors: Zhiwei Zheng Hongcai Chen Hongfu Cai Huide Zhu Source Type: research